ICON Reports Fourth Quarter and Full Year 2015 Results and Issues 2016 Earnings Guidance

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the fourth quarter and full year ended December 31, 2015.

In the fourth quarter net revenue grew 3.4% year on year to $403.3 million from $390.1 million in the same quarter last year. This represented 8.0% constant currency growth and 3.7% constant dollar organic growth year on year.

Income from operations in the quarter, increased by 24.7% to $73.3 million or 18.7% of revenue compared to $60.4 million or 15.5% for the same quarter last year.

Net income in the quarter increased by 17.5% to $63.4 million or $1.11 per share on a diluted basis, compared with $54.0 million or $0.87 per share for the same quarter last year.

Full year revenue increased by 4.8% to $1,575 million from $1,503.3 million in 2015. This represented 10.0% constant currency growth and 5.1% constant dollar organic growth year on year.

Full year income from operations increased by 33.3% to $281.5 million or 17.9% of revenue, compared with $211.1 million or 14.0% of revenue in the previous year.

Full year net income increased by 32.1% to $239.5 million, compared with $181.3 million last year. Full year earnings per share increased by 38.7% to a pro-forma $3.98 per share on a diluted basis compared to $2.87 per diluted share last year.

Full year diluted earnings per share on a US GAAP basis amounted to $3.97 compared to the pro-forma $3.98 as reported above. The difference occurs as a result of the method used to calculate the quarterly EPS versus annual EPS.

Day’s sales outstanding, comprising accounts receivable and unbilled revenue less payments on account were 41 days at December 31, 2015, compared with 46 days at the end of September 2015 and 40 days at the end of December 2014.

Cash generated from operating activities for the quarter was $116.1 million and $279.5 million for the full year. Capital expenditure for the quarter was $13.5 million and $49.7 million for the full year. During the quarter ICON spent $171 million on share repurchases which brought the value of total shares repurchased during 2015 to $459 million. In addition, $166 million was spent on acquisitions in 2015. As a result, at December 31, 2015, the company had net debt of $160 million, compared to net debt of $33 million at September 30, 2015 and net cash of $216 million at end of December 2014.

CEO, Ciaran Murray commented “During 2015, our operational excellence and market leading innovation helped our customers enhance the productivity of their development programmes, further enhancing ICON’s position as their trusted partner in drug development. As a result we booked $1.9 billion of new business and have grown our backlog by 9% year on year to $3.9 billion. Our revenues have grown by 10% on a constant currency basis to $1.575 billion and we have continued to expand our operating margin. This enabled us to grow EPS by 39% year on year to $3.98. For 2016, we are guiding revenue to be in the range of $1,670 - $1,730 million an increase of 6.0 -9.8%, and earnings to be in the range of $4.60 - $4.80 representing an increase of 15.6 – 20.6%”.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold its fourth quarter conference call today, February 23, 2016 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”. This calendar will be updated regularly.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 90 locations in 37 countries and has approximately 11,900 employees. Further information is available at www.iconplc.com.

ICON/ICLR-F